ESCONDIDO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- One Stop Systems, Inc. (Nasdaq: OSS), a leader in AI Transportable solutions on the edge, reported results for the first quarter ended March 31, 2023. All quarterly comparisons are to the same year-ago …
Data from Waldenstrom macroglobulinemia cohort selected for poster presentation at EHA2023 Outpatient treatment of follicular lymphoma selected for oral presentation at ICML WORCESTER, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) ( …
$10M suurune investeerimispreemia, mille eesmärk on mõtlemismasina praktiline rakendamine, mis tekitaks dünaamiliste mängukogemuste kaudu teaduslikke avastusi SAN FRANCISCO, CALIFORNIA, USA, May 11, 2023 /EINPresswire.com/ -- Mindrock avab 10 miljoni …
Minnesota State Advanced Manufacturing Center of Excellence hosts the 2MTEC conference on August 8-9m 2023 at Moorhead HS Career Academy BEMIDJI, MINNESOTA, USA, May 11, 2023 /EINPresswire.com/ -- The Minnesota State Advanced Manufacturing Center of …
IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Eleventh consecutive quarter of year-over-year growth, fueled by market outperformance in reconstruction Continued improvement in non-GAAP OPEX, adjusted EBITDA, and free cash flow performance demonstrating …
MALVERN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the …
Clinical updates on track for NKX101 in second quarter of 2023 at a company-hosted event and NKX019 in second half of 2023 Cash and cash equivalents of $332.1 million on March 31, 2023 Cash runway anticipated to fund operations into 2025 SOUTH SAN …
紐約, May 12, 2023 (GLOBE NEWSWIRE) -- 事因：全球投資者權益律師事務所 Rosen Law Firm 提醒於 2022 年 3 月 7 日至 2022 年 11 月 29 日（含上述兩日）（「集體訴訟期」）期間購買 Eqonex Limited（前稱 Diginex Limited）(OTC: EQOSQ) 證券之投資者，以及/或在 2021 年 4 月 8 日至 2023 年 4 月 20 日（「未登記證券集體訴訟期」）（統稱為「集體訴訟期」）購買未登記 EQO …
Seota Donates to The Poppy Project, a non-profit organization that provides support & resources to families who have suffered the loss of a pregnancy or child. FRISCO, TX, USA, May 11, 2023 /EINPresswire.com/ -- Frisco, TX – May 11, 2023 - Seota …
LEXINGTON, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from …
SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial …
Recent Highlights: Net revenues of $11.8 million in the first quarter of 2023, up 29% year-over-year Gross systems shipped of 8,705, up 51% year-over-year GAAP total operating loss $22.8 million in the first quarter of 2023, compared to $30.4 million in …
Completed dosing of the Phase 1 clinical trial of VYD222, a broadly neutralizing monoclonal antibody (mAb) candidate being developed to protect immunocompromised people from COVID-19 Initial data readouts from Phase 1 VYD222 clinical trial planned for Q2 …
Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn’s disease and psoriatic arthritis, with topline data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis is progressing …
NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) today announced that it will present at the following investor conferences. Goldman Sachs Global Staples Forum Tuesday, May 16, 2023 …
SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will present preliminary data from its Phase 1 dose …
VANCOUVER, British Columbia, May 11, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 2023 RBC Capital Markets Global Healthcare …
Advancing CAB-AXL BA3011 in ongoing sarcoma Phase 2 studies including a potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS); expect Leiomyosarcoma (LMS) cohort readout in 2H23 On track for submitting a meeting request to the Food …
Anticipate topline 16-week data for all three cohorts from the Phase 1b trial for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in the third quarter of 2023 IND-enabling studies for VYN202, a potential best-in-class oral small molecule BD2- …
— Delivered over $9 Million in Q1 revenue — Progressive bottom line improvement through Q1 ROMEOVILLE, Ill., May 11, 2023 (GLOBE NEWSWIRE) -- Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care …
